PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction [Irvine]
October 2, 2019
3800 S Plaza Dr.
Santa Ana, CA 92704
Wednesday, October 2, 2019
6:00 - 6:30 pm - Registration & Dinner
6:30 - 8:30 pm - Program
This symposium reviews current cardiovascular outcomes data for PCSK9 inhibitors, how to integrate non-statin lipid-lowering therapies and current cholesterol guidelines for the management of high CV-risk patients, and strategies for gaining access to PCSK9 inhibitors for high CV risk patients that need them.
In addition, attendees will have an opportunity to develop a treatment plan for real-world patients and compare and discuss their strategies with the faculty panel. Attendees are also encouraged to bring or submit difficult cases and questions to challenge the faculty in the “Stump the Faculty” segment.
This CME initiative will target Lipid Specialists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), nurse practitioners (NPs), physician assistants (PAs), and other healthcare providers who practice in a primary care setting.
- Assess current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events
- Integrate PCSK9 inhibitors in the management of real-world patients at high CV risk requiring additional LDL-C reduction
- Formulate strategies to improve patient access to PCSK9 inhibitors for those who require further CV risk reduction
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration.
Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Wednesday, October 2, 2019
|6:00-6:30pm||Registration & Complimentary Dinner|
|6:30-6:35pm||Welcome & Pre-activity Assessment|
PCSK9 Inhibitors: A New Option for Reducing Cardiovascular Events in High-Risk Patients?
|6:50-7:50pm||Challenging Cases: What would you do?
Real-world patient cases for group case workshop – develop and discuss treatment plan with faculty panel
|7:50-8:20pm||Stump the Faculty: Controversies and Challenges in Lipid Management
Bring or submit your difficult cases and questions to challenge the faculty
|8:20-8:30pm||Post-activity Assessment & Adjourn|
Rob Greenfield, MD, FACC, FAHA, FNLA
Assist Prof Medicine, UC-Irvine Medical Center
University of California Irvine
Senior Partner, Director Lipid Clinic
California Heart Associates
Fountain Valley, CA
Dr. Rob Greenfield is a co-founder and senior partner of California Heart Associates in Orange County, California. He is Board Certified in Internal Medicine, Cardiovascular Diseases, and Clinical Lipidology. He received his B.A. at the City University of New York, Brooklyn College, and his M.D. from the State University of New York- Downstate Medical Center, and cardiology fellowship at University of California, Irvine. He then went on to accept an academic position at UC-Irvine Medical Center as full-time faculty before co-founding California Heart Associates in 1979. After twenty-one years, he accepted a full-time faculty position in the Division of Cardiology and Director of the Cardiology Clinics at the Oregon Health Sciences University in Portland where he and his wife Audrey stayed for three years before returning to California Heart. He continues teaching and is a national and regional speaker for several pharmaceutical companies, and can periodically be heard on KFI-AM.
His research includes clinical lipidology, acute coronary syndrome, and risk factor modification. He is a Clinical Assistant Professor of Medicine at UC-Irvine Medical Center where he remains active in the Preventive Cardiology Clinics. He is Past President of the Board of Directors of the Pacific Chapter of the National Lipid Association and is the Past Chief-of-Staff at Orange Coast Memorial Medical Center and Director of their Non-Invasive Cardiology, and Preventive and Cardiac Rehabilitation programs. As California Heart Associates completes its 40th year, Dr. Greenfield's pursuits continue to include clinical lipidology, general cardiology, and prevention. He lives in Newport Coast with his wife Audrey of 51 years.
Disclosure - Dr. Rob Greenfield has served as a Speaker for Amgen, Sanofi and Regeneron.
Nathan Wong, PhD, FACC, FAHA, FNLA, FASPC
Professor and Director, Heart Disease Prevention Program
Division of Cardiology, University of California, Irvine
Dr. Nathan Wong is a cardiovascular epidemiologist and Professor and Director, Heart Disease Prevention Program, Division of Cardiology at the University of California, Irvine in California, with joint appointments in Epidemiology and UCLA and UC Irvine and Radiology and Public Health at UC Irvine. He holds MPH and PhD degrees in epidemiology from Yale University and is a fellow of the American College of Cardiology, American Heart Association, National Lipid Association, and American Society for Preventive Cardiology He is a past president of the American Society for Preventive Cardiology and Pacific Lipid Association (Chapter of the National Lipid Association), and president-elect of the Interamerican Heart Foundation. In addition, he serves as chair of the Diabetes Collaborative Registry Research and Publications Committee and editor of the ACC Diabetes and Cardiometabolic Clinical Topic Collection. In addition, Dr. Wong is an honorary member of the Academy of Nutrition and Dietetics, Academician of the Republic of Srpska (Bosnia and Herzegovina) Academy of Sciences and Arts and Full Professor of the European Center for Peace and Development. He is also a recipient of the Jan Kellerman Memorial Award for Achievement in Preventive Cardiology and Distinguished Fellowship Award of the International Academy of Cardiology.
Dr. Wong has primary research interests in subclinical atherosclerosis, lipid and diabetes management, and cardiovascular disease epidemiology and prevention and has authored over 300 papers and co-edited six textbooks, including the Braunwald Companion on Preventive Cardiology and the ASPC Manual on Preventive Cardiology. He is also on the editorial board of several cardiology and diabetes-related journals. Dr. Wong lectures locally, nationally and internationally on various topics in preventive cardiology.
Disclosure - Dr. Nathan Wong has served on a Speakers Bureau for Amarin and Sanofi. He has served on Advisory Boards for Amarin and Novartis.
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Preventive CV Medicine, Lipidology and Hypertension
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, Northeast Chapter National Lipid Association
NYU Langone Medical Center LLC
New York, NY
Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of general internal medicine and endocrinology at NYU. Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and President of the National Lipid Association. He is a Fellow of the National Lipid Association, A Fellow of the American College of Physicians, A Fellow of the NY Academy of Medicine and Vice President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the FH Foundation. Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.
Disclosure - Dr. Underberg has served on a Speakers Bureau for Amgen, Sanofi, Regeneron, Amarin, Akacea and Alexion. He has served as a Consultant for Amgen and Ambry and performed contracted research for Aegerion.
P. Barton Duell, MD
Dr. Duell’s special areas of interest include lipid disorders (e.g. high cholesterol), metabolic disorders, homocysteine metabolism, prevention of atherosclerosis (heart disease), diabetes, endocrinology and management of obesity. He currently serves as the director of OHSU’s Metabolic Disorders Clinic. He received his medical degree from OHSU in 1983, and completed his medicine residency at OHSU and the University of Chicago. He completed his metabolism, endocrinology and nutrition fellowship at the University of Washington in Seattle.
Disclosure - Dr. P. Barton Duell has served as a Consultant for Akcea, Astra Zeneca, Regeneron, Regenxbio, Esperion, and Retrophin. Institutional Grants were received from Regeneron, Regenxbio, Esperion and Retrophin.
Other Contributor/Planner Disclosures
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
How To Claim Credit
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the pre-test, post-test and activity evaluation
Statement of credit will be available to print from your user history page.